Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19
| Autor: | Hugo González-Conchillos, Gabriel Marcelino-Pérez, Daniela Roa-Velázquez, Edgar Morales-Ríos, Roberto Ruiz-Medrano, America Padilla-Viveros, Diana Tapia-Sidas, Martha Espinosa-Cantellano, Gustavo Torres-Franco, Karla Acosta-Virgen, Leandro Nuñez-Muñoz, Ana Olivares-Martínez, Jorge Ramos-Flores, Diana Peláez-González, Brenda Vargas-Hernández, José Abrahan Ramírez-Pool, Berenice Calderón-Pérez, Jorge Fernández-Hernández, Miriam Pérez-Saldívar, Beatriz Xoconostle-Cázares |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Glycosylation
prokaryotic expression Immunology viral glycosylation Spike protein medicine.disease_cause Article law.invention chemistry.chemical_compound Immune system Antigen law vaccine Drug Discovery medicine Pharmacology (medical) Escherichia coli Pharmacology receptor binding domain biology SARS-CoV-2 Fast protein liquid chromatography Virology Infectious Diseases chemistry Polyclonal antibodies Recombinant DNA biology.protein Medicine Antibody |
| Zdroj: | Vaccines Vaccines, Vol 9, Iss 928, p 928 (2021) Volume 9 Issue 8 |
| ISSN: | 2076-393X |
| Popis: | The Receptor-Binding Domain (RBD) of the Spike (S) protein from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has glycosylation sites which can limit the production of reliable antigens expressed in prokaryotic platforms, due to glycan-mediated evasion of the host immune response. However, protein regions without glycosylated residues capable of inducing neutralizing antibodies could be useful for antigen production in systems that do not carry the glycosylation machinery. To test this hypothesis, the potential antigens NG06 and NG19, located within the non-glycosylated S-RBD region, were selected and expressed in Escherichia coli, purified by FPLC and employed to determine their immunogenic potential through detection of antibodies in serum from immunized rabbits, mice, and COVID-19 patients. IgG antibodies from sera of COVID-19-recovered patients detected the recombinant antigens NG06 and NG19 (A450 nm = 0.80 ± 0.33 1.13 ± 0.33 and 0.11 ± 0.08 for and negatives controls, respectively). Also, the purified antigens were able to raise polyclonal antibodies in animal models evoking a strong immune response with neutralizing activity in mice model. This research highlights the usefulness of antigens based on the non-N-glycosylated region of RBD from SARS-CoV-2 for candidate vaccine development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|